{
  "docId": "019de075-e430-7299-a96e-811e562ad763",
  "docSlug": "dd1cc6bfd53a92cef2d40347c5bc25e6",
  "documentTitle": "Alkermes | Results Presentation Deck | 27 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 27,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e430-7299-a96e-811e562ad763/23",
  "deckHref": "/decks/019de075-e430-7299-a96e-811e562ad763",
  "deckJsonHref": "/decks/019de075-e430-7299-a96e-811e562ad763.json",
  "deckAnchorHref": "/decks/019de075-e430-7299-a96e-811e562ad763#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.065,
        "w": 0.888,
        "x": 0.056,
        "y": 0.219
      },
      "kind": "callout",
      "text": "Initial benefit/risk profile supports continued clinical evaluation of ALKS 2680",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "130e7921-7433-45c2-a9e9-c30491d4a3ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.75,
        "x": 0.195,
        "y": 0.575
      },
      "kind": "list",
      "text": "Generally well tolerated at all doses tested; drug-related adverse events only observed at highest dose (8 mg); Statistically significant, clinically meaningful, and durable improvement of sleep latency; Profile supportive of once-daily administration; Improvement in sleep latency observed at a low therapeutic dose targeted between 3 and 8 mg in narcolepsy type 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "332c1bef-684e-43d5-842c-8cebc5cf2bad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.75,
        "x": 0.195,
        "y": 0.325
      },
      "kind": "list",
      "text": "Generally well tolerated up to doses of 50 mg; Increased objective and subjective measures of alertness; PK/PD profile supports once-daily oral dosing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfa163c0-1224-4a5e-9aea-54b638491897",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.224,
        "x": 0.056,
        "y": 0.125
      },
      "kind": "title",
      "text": "Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05489b18-791d-426f-b2df-6238402c0424",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 13,
      "beatId": "a2d3f125-9d63-41e7-ad4b-d97f1d4906af",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The preliminary results from a Phase 1 study of ALKS 2680 demonstrate potential for growth",
      "position": 2,
      "confidence": 0.7,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}